GGrantIndex
← Search

Cancer Center Support Grant

$145,523P30FY2022CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-21-100. Elucidating B cell-mediated mechanisms of response and resistance to radiation therapy in soft tissue sarcoma Project Summary/Abstract Soft tissue sarcoma is a lethal mesenchymal cancer. Radiation therapy remains a cornerstone of treatment, but the immunologic basis of response and resistance to radiation therapy remains poorly understood. Historically, research on radiation treatment has largely focused on methodological issues of its delivery (e.g., optimizing dose and fractionation) and the effects of ionizing radiation on tumor cells, with less focus on the impact of radiation on the intratumoral and systemic immune response. Presumptive immune-mediated consequences of radiation—such as the abscopal effect and higher incidence of surgical wound infection after radiation—are well documented in the clinic, but the mechanistic basis of these phenomena are not understood. Here we propose to longitudinally characterize the human immune response to radiation (e.g. baseline, on-treatment, post-treatment) in sarcoma patients and further investigate these findings in animal models of sarcoma. We are particularly interested in the humoral immune response because emerging data show a strong association between B cells and high antibody titers with response to immunotherapy and survival in sarcoma patients. We will provide a comprehensive view of the complex humoral response to radiation treatment by using a variety of genomic-based, biochemical, and functional assays to gain insight into the developmental history, phenotype, and function of intratumoral and circulating B cell populations. This will potentially inform the design of humoral-based therapies that can be used in combination with radiation treatment for sarcoma patients.

View original record on NIH RePORTER →